Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2025-03-28 | 2025-03-11 |
| Drug Identification Number | 02435136 | 02435136 |
| Brand name | SYLVANT | SYLVANT |
| Common or Proper name | SYLVANT | SYLVANT |
| Company Name | RECORDATI RARE DISEASES CANADA INC | RECORDATI RARE DISEASES CANADA INC |
| Ingredients | SILTUXIMAB | SILTUXIMAB |
| Strength(s) | 400MG | 400MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 1 X 30 ML vial | 1 X 30 ML vial |
| ATC code | L04AC | L04AC |
| ATC description | IMMUNOSUPPRESSANTS | IMMUNOSUPPRESSANTS |
| Reason for shortage | Requirements related to complying with good manufacturing practices. | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | ||
| Actual start date | 2025-03-06 | 2025-03-06 |
| Estimated end date | 2025-03-31 | 2025-03-31 |
| Actual end date | 2025-03-27 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | 100 mg/vial strength is available for distribution and can be used in place of the 400 mg/vial until the stock is available. | 100 mg/vial strength is available for distribution and can be used in place of the 400 mg/vial until the stock is available. |
| Health Canada comments |